USANA Health Sciences (NYSE:USNA) Upgraded by Wall Street Zen to “Buy” Rating

USANA Health Sciences (NYSE:USNA) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

USNA has been the topic of several other reports. Zacks Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

USANA Health Sciences Stock Performance

USNA stock opened at $19.00 on Friday. The stock has a market cap of $350.74 million, a P/E ratio of 40.43, a P/E/G ratio of 0.74 and a beta of 0.76. The firm has a 50 day simple moving average of $18.77 and a 200 day simple moving average of $19.41. USANA Health Sciences has a 52 week low of $16.60 and a 52 week high of $38.32.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.17. The firm had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Sell-side analysts predict that USANA Health Sciences will post 2.12 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the sale, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Brent Neidig sold 5,002 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 17,660 shares of company stock valued at $336,579. 0.82% of the stock is currently owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

Several hedge funds have recently bought and sold shares of USNA. Empowered Funds LLC lifted its position in shares of USANA Health Sciences by 9.7% in the first quarter. Empowered Funds LLC now owns 66,293 shares of the company’s stock worth $1,158,000 after buying an additional 5,856 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of USANA Health Sciences during the 1st quarter worth about $1,265,000. Sei Investments Co. increased its holdings in shares of USANA Health Sciences by 98.8% during the 1st quarter. Sei Investments Co. now owns 59,730 shares of the company’s stock valued at $1,043,000 after acquiring an additional 29,691 shares during the last quarter. State of Wyoming acquired a new position in shares of USANA Health Sciences during the 1st quarter valued at about $57,000. Finally, First Trust Advisors LP increased its holdings in shares of USANA Health Sciences by 17.7% during the 1st quarter. First Trust Advisors LP now owns 14,784 shares of the company’s stock valued at $258,000 after acquiring an additional 2,227 shares during the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.